A review of combined treatments for melasma involving energy-based devices and proposed pathogenesis-oriented combinations.
Journal
Journal of cosmetic dermatology
ISSN: 1473-2165
Titre abrégé: J Cosmet Dermatol
Pays: England
ID NLM: 101130964
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
revised:
27
02
2021
received:
19
10
2020
accepted:
15
03
2021
pubmed:
2
4
2021
medline:
5
2
2022
entrez:
1
4
2021
Statut:
ppublish
Résumé
Melasma is an acquired disorder of hyperpigmentation, affecting a million individuals worldwide. Energy-based devices (EBDs) employed to treat melasma include various types of lasers, intense pulsed light (IPL), and radiofrequency (RF). Recent studies have attempted to address recalcitrant and recurring melasma by combining energy-based devices with topical or oral medications. This article reviews EBDs-based augmented treatment for melasma and suggests practical pathogenesis-oriented treatment regimens. Treatment algorithms are proposed to address various components of melasma. A systematic PubMed search was conducted acquiring information from various studies on combination treatments of melasma involving EBDs. The 286 retrieved articles were filtered by title to contain at least one type of energy-based modality such as laser, IPL, or RF along with at least one other treatment method. Based on their subject matter, combinations were further categorized into the subheadings: laser plus medication, laser plus laser, and IPL- and RF-containing treatment methods. There are many energy-based combination treatments that have been explored for mitigation of melasma including laser therapy with medication, multi-laser therapies, IPL, RF, and microneedling devices. Melasma is an exceedingly difficult condition to treat, however, choosing the appropriate tailor-made treatment combination can improve the final outcome.
Sections du résumé
BACKGROUND
BACKGROUND
Melasma is an acquired disorder of hyperpigmentation, affecting a million individuals worldwide. Energy-based devices (EBDs) employed to treat melasma include various types of lasers, intense pulsed light (IPL), and radiofrequency (RF). Recent studies have attempted to address recalcitrant and recurring melasma by combining energy-based devices with topical or oral medications.
OBJECTIVE
OBJECTIVE
This article reviews EBDs-based augmented treatment for melasma and suggests practical pathogenesis-oriented treatment regimens. Treatment algorithms are proposed to address various components of melasma.
METHODS
METHODS
A systematic PubMed search was conducted acquiring information from various studies on combination treatments of melasma involving EBDs.
RESULTS
RESULTS
The 286 retrieved articles were filtered by title to contain at least one type of energy-based modality such as laser, IPL, or RF along with at least one other treatment method. Based on their subject matter, combinations were further categorized into the subheadings: laser plus medication, laser plus laser, and IPL- and RF-containing treatment methods.
CONCLUSION
CONCLUSIONS
There are many energy-based combination treatments that have been explored for mitigation of melasma including laser therapy with medication, multi-laser therapies, IPL, RF, and microneedling devices. Melasma is an exceedingly difficult condition to treat, however, choosing the appropriate tailor-made treatment combination can improve the final outcome.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
461-472Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Rendon M, Berneburg M, Arellano I, Picardo M. Treatment of melasma. J Am Acad Dermatol. 2006;54(5 Suppl 2):S272-S281.
Kang HY, Ortonne J-P. What should be considered in treatment of melasma. Ann Dermatol. 2010;22(4):373.
Vashi NA, Kundu RV. Facial hyperpigmentation: causes and treatment. Br J Dermatol. 2013;169:41-56.
Kang HY, Bahadoran P, Suzuki I, et al. In vivo reflectance confocal microscopy detects pigmentary changes in melasma at a cellular level resolution. Exp Dermatol. 2010;19(8):e228-e233.
Kim EH, Kim YC, Lee E-S, Kang HY. The vascular characteristics of melasma. J Dermatol Sci. 2007;46(2):111-116.
Sanchez NP, Pathak MA, Sato S, Fitzpatrick TB, Sanchez JL, Mihm MC. Melasma: A clinical, light microscopic, ultrastructural, and immunofluorescence study. J Am Acad Dermatol. 1981;4(6):698-710.
Kang WH, Yoon KH, Lee ES, et al. Melasma: histopathological characteristics in 56 Korean patients. Br J Dermatol. 2002;146(2):228-237.
Grimes PE, Yamada N, Bhawan J. Light microscopic, immunohistochemical, and ultrastructural alterations in patients with melasma. Am J Dermatopathol. 2005;27(2):96-101.
Torres-Álvarez B, Mesa-Garza IG, Castanedo-Cázares JP, et al. Histochemical and immunohistochemical study in melasma: evidence of damage in the basal membrane. Am J Dermatopathol. 2011;33(3):291-295.
Trivedi MK, Yang FC, Cho BK. A review of laser and light therapy in melasma. Int J Womens Dermatol. 2017;3(1):11-20.
Mansouri P, Farshi S, Hashemi Z, Kasraee B. Evaluation of the efficacy of cysteamine 5% cream in the treatment of epidermal melasma: a randomized double-blind placebo-controlled trial. Br J Dermatol. 2015;173(1):209-217.
Lee HC, Thng TGS, Goh CL. Oral tranexamic acid (TA) in the treatment of melasma: a retrospective analysis. J Am Acad Dermatol. 2016;75(2):385-392.
Shin JU, Park J, Oh SH, Lee JH. Oral tranexamic acid enhances the efficacy of low-fluence 1064-nm quality-switched neodymium-doped yttrium aluminum garnet laser treatment for melasma in Koreans: a randomized, prospective trial. Dermatol Surg. 2013;39(3 Pt 1):435-442.
Kwon HH, Ohn J, Suh DH, et al. A pilot study for triple combination therapy with a low-fluence 1064 nm Q-switched Nd:YAG laser, hydroquinone cream and oral tranexamic acid for recalcitrant Riehl's Melanosis. J Dermatolog Treat. 2017;28(2):155-159.
Laothaworn V, Juntongjin P. Topical 3% tranexamic acid enhances the efficacy of 1064-nm Q-switched neodymium-doped yttrium aluminum garnet laser in the treatment of melasma. J Cosmet Laser Ther. 2018;20(6):320-325.
Jeong S-Y, Shin J-B, Yeo U-C, Kim W-S, Kim I-H. Low-fluence Q-switched neodymium-doped yttrium aluminum garnet laser for melasma with pre- or post-treatment triple combination cream. Dermatol Surg. 2010;36(6):909-918.
Draelos ZD. Low-fluence Q-switched neodymium-doped yttrium aluminum garnet laser for melasma with pre- or post-treatment triple combination cream. Dermatol Surg. 2011;37(1):126-127.
Tourlaki A, Galimberti MG, Pellacani G, Bencini PL. Combination of fractional erbium-glass laser and topical therapy in melasma resistant to triple-combination cream. J Dermatolog Treat. 2014;25(3):218-222.
Trelles MA, Velez M, Gold MH. The treatment of melasma with topical creams alone, CO2 fractional ablative resurfacing alone, or a combination of the two: a comparative study. J Drugs Dermatol. 2010;9(4):315-322.
Park KY, Kim DH, Kim HK, Li K, Seo SJ, Hong CK. A randomized, observer-blinded, comparison of combined 1064-nm Q-switched neodymium-doped yttrium-aluminium-garnet laser plus 30% glycolic acid peel vs. laser monotherapy to treat melasma. Clin Exp Dermatol. 2011;36(8):864-870.
Saleh F, Moftah NH, Abdel-Azim E, Gharieb MG. Q-switched Nd: YAG laser alone or with modified Jessner chemical peeling for treatment of mixed melasma in dark skin types: A comparative clinical, histopathological, and immunohistochemical study. J Cosmet Dermatol. 2018;17(3):319-327.
Lee DB, Suh HS, Choi YS. A comparative study of low-fluence 1064-nm Q-switched Nd:YAG laser with or without chemical peeling using Jessner's solution in melasma patients. J Dermatolog Treat. 2014;25(6):523-528.
Vachiramon V, Sahawatwong S, Sirithanabadeekul P. Treatment of melasma in men with low-fluence Q-switched neodymium-doped yttrium-aluminum-garnet laser versus combined laser and glycolic acid peeling. Dermatol Surg. 2015;41(4):457-465.
Kauvar ANB. Successful treatment of melasma using a combination of microdermabrasion and Q-switched Nd:YAG lasers. Lasers Surg Med. 2012;44(2):117-124.
Chen Y-T, Chang C-C, Hsu C-R, Shen J-H, Shih C-J, Lin B-S. Combined vitamin C sonophoresis and neodymium-doped yttrium aluminum garnet (NdYAG) laser for facial hyperpigmentation: an outcome observation study in Asian patients. Indian J Dermatol Venereol Leprol. 2016;82(5):587.
Lee M-C, Chang C-S, Huang Y-L, et al. Treatment of melasma with mixed parameters of 1,064-nm Q-switched Nd:YAG laser toning and an enhanced effect of ultrasonic application of vitamin C: a split-face study. Lasers Med Sci. 2015;30(1):159-163.
Zhou HL, Hu B, Zhang C. Efficacy of 694-nm fractional Q-switched ruby laser (QSRL) combined with sonophoresis on levorotatory vitamin C for treatment of melasma in Chinese patients. Lasers Med Sci. 2016;31(5):991-995.
Wu Y-H, Li Q-L, Yang X-W. Effects of Chinese herbal medicine combined with He-Ne laser on lipoperoxide and superoxide dismutase in chloasma patients. J Tradit Chin Med. 2009;29(3):163-166.
Jin Y, Jiang W, Yao Y, Huang H, Huang J. Clinical efficacy of laser combined with menstrual regulation in the treatment of female melasma: a retrospective study. Lasers Med Sci. 2019;34(6):1099-1105.
Polnikorn N. Treatment of refractory melasma with the MedLite C6 Q-switched Nd:YAG laser and alpha arbutin: a prospective study. J Cosmet Laser Ther. 2010;12(3):126-131.
Abdel-Raouf Mohamed H, Ali Nasif G, Saad Abdel-Azim E, Abd El-Fatah Ahmed M. Comparative study of fractional Erbium: YAG laser vs combined therapy with topical steroid as an adjuvant treatment in melasma. J Cosmet Dermatol. 2019;18(2):517-523.
Kim HS, Kim EK, Jung KE, Park YM, Kim HO, Lee JY. A split-face comparison of low-fluence Q-switched Nd: YAG laser plus 1550 nm fractional photothermolysis vs. Q-switched Nd: YAG monotherapy for facial melasma in Asian skin. J Cosmet Laser Ther. 2013;15(3):143-149.
Kong SH, Suh HS, Choi YS. Treatment of melasma with pulsed-dye laser and 1,064-nm Q-switched Nd:YAG laser: a split-face study. Ann Dermatol. 2018;30(1):1-7.
Nouri K, Bowes L, Chartier T, Romagosa R, Spencer J. Combination treatment of melasma with pulsed CO2 laser followed by Q-switched alexandrite laser: a pilot study. Dermatol Surg. 1999;25(6):494-497.
Angsuwarangsee S, Polnikorn N. Combined ultrapulse CO2 laser and Q-switched alexandrite laser compared with Q-switched alexandrite laser alone for refractory melasma: split-face design. Dermatol Surg. 2003;29(1):59-64.
Choi Y-J, Nam J-H, Kim JY, et al. Efficacy and safety of a novel picosecond laser using combination of 1 064 and 595 nm on patients with melasma: a prospective, randomized, multicenter, split-face, 2% hydroquinone cream-controlled clinical trial. Lasers Surg Med. 2017;49(10):899-907.
Geddes ER, Stout AB, Friedman PM. Long-pulsed dye laser of 595 nm in combination with pigment-specific modalities for a patient exhibiting increased vascularity within lesions of melasma. Dermatol Surg. 2016;42(4):556-559.
Geddes ERC, Stout AB, Friedman PM. Retrospective analysis of the treatment of melasma lesions exhibiting increased vascularity with the 595-nm pulsed dye laser combined with the 1927-nm fractional low-powered diode laser. Lasers Surg Med. 2017;49(1):20-26.
Shakeeb N, Noor SM, Ullah G, Paracha MM. Efficacy of intense pulse light therapy and tripple combination cream versus intense pulse light therapy and tripple combination cream alone in epidermal melasma treatment. J Coll Physicians Surg Pak. 2018;28(1):13-16.
Figueiredo Souza L, Trancoso SS. Single-session intense pulsed light combined with stable fixed-dose triple combination topical therapy for the treatment of refractory melasma. Dermatol Ther. 2012;25(5):477-480.
Goldman MP, Gold MH, Palm MD, et al. Sequential treatment with triple combination cream and intense pulsed light is more efficacious than sequential treatment with an inactive (control) cream and intense pulsed light in patients with moderate to severe melasma. Dermatol Surg. 2011;37(2):224-233.
Chung JY, Lee JH, Lee JH. Topical tranexamic acid as an adjuvant treatment in melasma: side-by-side comparison clinical study. J Dermatol Treat. 2015;27(4):373-377.
Yun WJ, Moon H-R, Lee M-W, Choi J-H, Chang S-E. Combination treatment of low-fluence 1,064-nm Q-switched Nd: YAG laser with novel intense pulse light in Korean melasma patients: a prospective, randomized, controlled trial. Dermatol Surg. 2014;40(8):842-850.
Vachiramon V, Sirithanabadeekul P, Sahawatwong S. Low-fluence Q-switched Nd: YAG 1064-nm laser and intense pulsed light for the treatment of melasma. J Eur Acad Dermatol Venereol. 2015;29(7):1339-1346.
Tong L-G, Wu Y, Wang B, et al. Combination of fractional QSRL and IPL for melasma treatment in Chinese population. J Cosmet Laser Ther. 2017;19(1):13-17.
Kwon HH, Choi SC, Jung JY, Park G-H. Combined treatment of melasma involving low-fluence Q-switched Nd:YAG laser and fractional microneedling radiofrequency. J Dermatol Treat. 2019;30(4):352-356.
Jung JW, Kim WO, Jung HR, Kim SA, Ryoo YW. A face-split study to evaluate the effects of microneedle radiofrequency with Q-switched Nd:YAG laser for the treatment of melasma. Ann Dermatol. 2019;31(2):133.
Ustuner P, Balevi A, Ozdemir M. A split-face, investigator-blinded comparative study on the efficacy and safety of Q-switched Nd:YAG laser plus microneedling with vitamin C versus Q-switched Nd:YAG laser for the treatment of recalcitrant melasma. J Cosmet Laser Ther. 2017;19(7):383-390.
Cameli N, Abril E, Mariano M, Berardesca E. Combined use of monopolar radiofrequency and transdermal drug delivery in the treatment of melasma. Dermatol Surg. 2014;40(7):748-755.
Xu Y, Ma R, Juliandri J, et al. Efficacy of functional microarray of microneedles combined with topical tranexamic acid for melasma. Medicine. 2017;96(19):e6897.
Budamakuntla L, Loganathan E, Suresh D, et al. A randomised, open-label, comparative study of tranexamic acid microinjections and tranexamic acid with microneedling in patients with melasma. J Cutan Aesthet Surg. 2013;6(3):139.
Kaur ABM. Topical tranexamic acid with microneedling in melasma. Acta Scientific Med Sci. 2019;3(4):124-126.
Parkinson LG, Toro A, Zhao H, Brown K, Tebbutt SJ, Granville DJ. Granzyme B mediates both direct and indirect cleavage of extracellular matrix in skin after chronic low-dose ultraviolet light irradiation. Aging Cell. 2014;14(1):67-77.
Kaur H, Aggarwal G, Nagpal M. Potential benefits of phytochemicals for treatment of hyperpigmentation. J Drug Delivery Therapeutics. 2019;9(2):420-427.
Kim JY, Kim JY, Jenis J, et al. Tyrosinase inhibitory study of flavonolignans from the seeds of Silybum marianum (Milk thistle). Bioorg Med Chem. 2019;27(12):2499-2507.
Altaei T. The treatment of melasma by silymarin cream. BMC Dermatol. 2012;12:18.
Elfar N, El-Maghraby G. Efficacy of intradermal injection of tranexamic acid, topical silymarin and glycolic acid peeling in treatment of melasma: a comparative study. J Clin Exp Dermatol Res. 2015;6(280):2.
Barolet D. Dual effect of photobiomodulation on melasma: downregulation of hyperpigmentation and enhanced solar resistance-A pilot study. J Clin Aesthet Dermatol. 2018;11(4):28-34.